Kt Corporation ADR Stock
Your prediction
Kt Corporation ADR Stock
The price for the Kt Corporation ADR stock decreased slightly today. Compared to yesterday there is a change of -€0.100 (-0.610%).
Pros and Cons of Kt Corporation ADR in the next few years
Pros
?
M***** P*******
?
B****
?
S********** s********
Cons
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Kt Corporation ADR vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Kt Corporation ADR | -0.610% | 2.532% | 5.882% | -7.429% | 2.532% | 47.273% | 32.787% |
| Freenet AG | 1.600% | 1.022% | -1.902% | -15.946% | -19.593% | 11.362% | 15.764% |
| Telecom New Zealand ADR | 0.420% | -2.429% | 2.553% | -23.492% | -13.153% | -65.324% | -65.324% |
| Philippine Long Distance Telephone Company ADR | -1.230% | -3.529% | -4.651% | -14.583% | -8.889% | -16.327% | -20.388% |
News
Kymera Therapeutics Q2 Earnings Call Highlights
Key Points
- Interested in Kymera Therapeutics, Inc.? Here are five stocks we like better.
- KT-621 atopic dermatitis trial enrollment is complete about six months ahead of schedule, with top-line
Kymera's CEO Sold $6 Million in Stock After a 170% Run
Chief Executive Officer Nello Mainolfi sold 50,000 shares of Kymera Therapeutics (NASDAQ:KYMR) on July 7, 2026, for total proceeds of about $6.0 million, according to an SEC Form 4 filing.
Kymera
Why Kymera Therapeutics Stock Popped This Week
This week was an eventful one for Kymera Therapeutics (NASDAQ: KYMR). The clinical-stage biotech announced the early completion of enrollment in an important clinical trial. It also earned a clutch